

Sponsor: Vifor (International) Inc.
Compound name: VIT-2763 (Vamifeport)
Protocol Number: VIT-2763-THAL-203
Protocol Title: A Phase 2b, double-blind, randomised, placebo-controlled, multicentre study to assess the efficacy and safety of VIT-2763 multiple doses in adults with transfusion-dependent β -thalassaemia
EudraCT Number: 2021-001639-23

Statement

This statement is to confirm that the above clinical study has been early terminated by the Sponsor due to strategic reasons.

No subject was randomised or received any study medication; no AE was reported.

CONTACT

Vifor Pharma Group
Vifor (International) Inc.
Rechenstrasse 37
CH-9014 St. Gallen

Phone +41 58 851 84 84
Fax +41 58 851 85 88